Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-arm study of teverelix DP in advanced prostate cancer
2023-509255-14-01Phase 2Authorised
- Sponsor
- Antev
- Start
- Apr 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teverelix in prostate cancer (PCa), sponsored by Antev. Primary endpoint: Sustained castration rate at testosterone threshold <= 0.5 ng/mL. Planned start Apr 2024; status: authorised.
02
Drugs
teverelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-509255-14-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509255-14-01.